Przeglądanie według Autor "Vityala, Yethindra"

Aktualnie wyświetlane 1 - 3 z 3

Clinical significance of serum interleukin-6 levels in patients with chronic kidney disease
(Publishing Office of the University of Rzeszow, 2024-09) Chokkavarapu, Renuka Charan; Bachireddy, Parimala; Billa, Vaibhavi Reddy; Vityala, Yethindra
Introduction and aim. Elevated levels of interleukin-6 (IL-6) in serum and kidney tissues are associated with the development and progression of chronic kidney disease (CKD). Although the role of pro-inflammatory cytokines, such as IL-6, in the development of cardiovascular complications is well studied, the relationship between serum IL-6 levels and CKD markers remains unclear. This study investigated the clinical significance of serum IL-6 levels in patients with CKD. Material and methods. Participants were divided into two groups based on estimated glomerular filtration rate (eGFR): group 1 (n=86) with eGFR >60 mL/min and group 2 (n=74) with eGFR <60 mL/min. The CKD Epidemiology Collaboration equation was used to calculate eGFR from serum creatinine and cystatin C levels to assess CKD severity. Results. Systolic blood pressure was higher in Group 2 than in Group 1 (138±22 mmHg vs. 129±19 mmHg; p<0.05). Serum IL-6 levels were also higher in group 2 (3.095 [interquartile range: 1.528–6.547] pg/mL) than in group 1 (1.711 [interquartile range: 0.920– 3.342] pg/mL; p <0.05). Serum IL-6 levels were strongly correlated with eGFR in multivariable-adjusted linear regression analysis. Conclusion. IL-6 levels increased in patients with CKD with an eGFR <60 mL/min, and this increase was associated with eGFR and diastolic blood pressure.
Pathophysiology of thromboembolism in patients with COVID-19
(Wydawnictwo Uniwersytetu Rzeszowskiego, 2022) Vityala, Yethindra; Krishna, Abhijit; Pandla, Dinesh; Priya Kanteti, Krishna; Sadhu, Jahnavi; Boddeti, Harsha Vardhan; Kintali, Tejesh; Khalid, Mohammad Shaour
Introduction and aim. A small number of critically ill patients with coronavirus disease (COVID-19) develop thromboembolism (arterial or venous), both micro- and macrovascular complications such as deep vein thrombosis, pulmonary embolism, and pulmonary arterial thrombosis. The objective of the study is to describe the pathophysiology of venous thromboembolism in patients with COVID-19. Material and methods. In this article a narrative review regarding pathophysiology of thromboembolism in patients with COVID-19. Analysis of the literature. The development of coagulopathy is a consequence of the intense inflammatory response associated with hypercoagulability, platelet activation, and endothelial dysfunction. The pathophysiology that relates pulmonary thromboembolism (PTE) with COVID-19 is associated with a hypercoagulable state. PTE is suspected in hospitalized patients presenting dyspnea, decreased oxygen requirement, hemodynamic instability, and dissociation between hemodynamic and respiratory changes. In COVID-19-associated coagulopathy, initially, patients present with elevated levels of fibrinogen and D-dimer, with minimal changes in prothrombin time and platelet count. The main risk factor for the development of pulmonary embolism is the increase in D-dimer that is associated with the development of PTE. The administration of iodine-based contrast agent to patients with COVID-19 would affect P-creatinine and renal function, where Ultrasound is viewed as cost-effective and highly portable, can be performed at the bedside. Conclusion. Acute respiratory distress syndrome severity in patients with COVID-19 can explain PTE as a consequence of an exaggerated immune response.
Therapeutic advantages of omega-3 fatty acid supplementation in patients with schizophrenia – a systematic review
(Publishing Office of the University of Rzeszow, 2024-03) Vityala, Srilaxmi; Kanteti, Krishna Priya; Vityala, Yethindra; Tagaev, Tugolbai; Damineni, Ujwala
Introduction and aim. In patients with schizophrenia, omega-3 (n-3) polyunsaturated fatty acids (PUFAs) treatment was found to ameliorate the cardiovascular, metabolic, and inflammatory problems caused by antipsychotic medication and even reduce the need for medication by 20%. In this study, we evaluated the potential therapeutic effects of n-3 PUFA supplementation in patients with schizophrenia. Material and methods. The PRISMA guidelines were followed in conducting this systematic review. The Embase, MEDLINE, Web of Science, and Google Scholar databases were searched electronically. The first search yielded 50 papers in total. Subse quently, 43 publications that did not meet our eligibility requirements were removed, and seven articles were selected. Analysis of the literature. The analysis showed that n-3 PUFA supplementation and the placebo group both decreased their psychotic (PANSS and GAF scales) and Calgary Depression Scale symptomatology and boosted their functional ability (GAF) when used as an adjuvant to antipsychotic medication. When administered as a monotherapy with a metabolic antioxidant, n-3 PUFA supplementation proved beneficial for treating schizophrenia. In patients with schizophrenia, n-3 PUFAs have thera peutic benefits as adjuvant treatments to medications, although not for different variables or patient groups. Conclusion. In many studies, patients with chronic schizophrenia who received n-3 PUFA supplementation showed no improvement in their clinical condition.